Carbamic acid, [2-(4-morpholinyl)ethyl]- | 854893-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: Carbamic acid, [2-(4-morpholinyl)ethyl]-
• 英文别名: 2-Morpholin-4-ylethylcarbamic acid
• CAS: 854893-19-9
• 化学式: C₇H₁₄N₂O₃
• 分子量: 174.2
• InChiKey: LFSBYVCXHQKTFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
  申请人：AMGEN INC

  公开号：WO2018183418A1

  公开（公告）日：2018-10-04

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的化学式（I）或其立体异构体；以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
• [EN] HYPOXIA ACTIVATED PRODRUGS OF BIS-ALKYLATING AGENTS<br/>[FR] PROMÉDICAMENTS ACTIVÉS PAR L'HYPOXIE À BASE D'AGENTS BIS-ALKYLANTS
  申请人：THRESHOLD PHARMACEUTICALS INC

  公开号：WO2009033165A1

  公开（公告）日：2009-03-12

  Hypoxia activated prodrug compounds of bis-alkylating agents are useful in the treatment of cancer and other hyperproliferative diseases.

  缺氧激活的双烷基化剂前药化合物在癌症和其他高增殖性疾病的治疗中是有用的。
• Acridine derivatives and their use as medicaments
  申请人：Gerlach Matthias

  公开号：US20050009809A1

  公开（公告）日：2005-01-13

  The invention relates to novel acridine derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for the treatment of tumors.

  该发明涉及公式1的新颖喹啉衍生物，其制备以及作为药物的用途，特别是用于肿瘤治疗。
• [EN] CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS<br/>[FR] CERTAINES ENTITÉS CHIMIQUES, COMPOSITIONS ET PROCÉDÉS
  申请人：NEUPHARMA INC

  公开号：WO2013023145A1

  公开（公告）日：2013-02-14

  Chemical entities that are arctigenin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. Treatment encompasses administration of at least one compound of Formula I, or a pharmaceutically acceptable salt thereof, to a mammalian subject, particularly a human subject, in need of such an administration and includes (i) arresting the development of clinical symptoms of the disease, such as cancer, (ii) bringing about a regression in the clinical symptoms of the disease, such as cancer, and/or (iii) prophylactic treatment for preventing the onset of the disease, such as cancer. Cancer refers to all types of cancer o neoplasm or malignant tumors found in mammals, including carcinomas and sarcomas. Examples of cancer are cancer of the brain, breast, cervix, colon, head & neck, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus and Medulloblastoma.

  描述了阿尔卡蒂根衍生物的化学实体、制药组合物和治疗癌症的方法。治疗包括向需要这种治疗的哺乳动物主体，特别是人类主体，施用至少一种I式化合物或其药学上可接受的盐，包括（i）阻止疾病的临床症状的发展，如癌症，（ii）导致疾病的临床症状退化，如癌症，和/或（iii）预防性治疗，以预防疾病的发生，如癌症。癌症指哺乳动物中发现的各种癌症或恶性肿瘤，包括癌瘤和肉瘤。癌症的例子包括脑癌、乳腺癌、子宫颈癌、结肠癌、头颈癌、肾癌、肺癌、非小细胞肺癌、黑色素瘤、间皮瘤、卵巢癌、肉瘤、胃癌、子宫癌和髓母细胞瘤。
• CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
  申请人：QIAN XIANGPING

  公开号：US20120196842A1

  公开（公告）日：2012-08-02

  Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.

  本文描述了新化合物、制药组合物和治疗癌症的方法。